Gritstone Oncology, a preclinical biotech developing a therapy that enhances checkpoint immuno-oncology drugs, filed on Thursday with the SEC to raise up to $80 million in an initial public offering.
The Emeryville, CA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol GRTS. Goldman Sachs, Cowen and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
